Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin
Abstract
We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. Forty-nine children (mean age at enrollment, …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
Infant
Comparative Study
newborn
risk factors
Clinical Trial
Randomized Controlled Trial
immunoglobulins
intravenous / adverse effects
intravenous / therapeutic use*
respirovirus infections / prevention & control*
immunoglobulin a / analysis
respiratory tract infections / microbiology
intravenous
respiratory syncytial viruses*
infusions
respiratory tract infections / prevention & control*
d r snydman
pmid:8215279
pmc188036
doi:10.1128/aac.37.8.1655
h c meissner
d r fulton
diseases / prevention & control
premedication
Access
Citation
ID:
119058
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
119058
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet